Aditxt Strengthens Board with Appointment of Women’s Health Leader Saundra Pelletier
TL;DR
Aditxt Inc. strengthens its board with Saundra Pelletier, leveraging her 30 years in pharma to gain a competitive edge in women’s health innovation.
Aditxt Inc. appoints Saundra Pelletier to its Board, enhancing its strategy with her expertise in women’s health and pharmaceutical brand growth.
Aditxt Inc.’s focus on women’s health, bolstered by Saundra Pelletier’s appointment, aims to improve global health outcomes and empower women.
Saundra Pelletier joins Aditxt Inc., bringing decades of pharma experience and a track record of successful women’s health product launches.
Found this article helpful?
Share it with your network and spread the knowledge!
Aditxt (NASDAQ: ADTX) has taken a significant step towards bolstering its expertise in women’s health with the appointment of Saundra Pelletier to its Board of Directors. Pelletier, the CEO of Evofem Biosciences (OTCPK: EVFM), brings over three decades of global pharmaceutical experience, particularly in women’s reproductive health. Her leadership at Evofem was instrumental in the approval and commercial success of Phexxi(R) and the acquisition of SOLOSEC(R), achieving four consecutive years of net sales growth. Pelletier’s extensive background and her roles on the boards of Windtree Therapeutics (NASDAQ: WINT) and various nonprofit organizations focused on women’s empowerment and health, position her as a valuable addition to Aditxt’s board.
This strategic move aligns with Aditxt’s broader mission to accelerate promising health innovations through its unique ecosystem of research institutions, industry partners, and shareholders. The company is currently advancing two programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health. Aditxt’s collaboration with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) and its merger agreement with Evofem are pivotal to these initiatives, although the completion of these transactions is contingent upon several conditions, including shareholder approval and sufficient capital raising.
The appointment of Pelletier underscores Aditxt’s commitment to addressing urgent health challenges through innovative solutions. Her expertise is expected to play a critical role in the company’s efforts to commercialize its health innovations and expand its focus on women’s health. For more details on Aditxt’s initiatives and Pelletier’s appointment, visit https://ibn.fm/8pefM.
Curated from InvestorBrandNetwork (IBN)
